S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
NASDAQ:ACST

Acasti Pharma (ACST) Stock Price, News & Analysis

$3.40
+0.02 (+0.59%)
(As of 03/18/2024 ET)
Today's Range
$3.36
$3.41
50-Day Range
$2.18
$3.48
52-Week Range
$1.72
$3.84
Volume
16,140 shs
Average Volume
25,999 shs
Market Capitalization
$31.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Acasti Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
76.5% Upside
$6.00 Price Target
Short Interest
Healthy
0.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of Acasti Pharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.44) to ($1.29) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.77 out of 5 stars

Medical Sector

472nd out of 947 stocks

Pharmaceutical Preparations Industry

223rd out of 435 stocks

ACST stock logo

About Acasti Pharma Stock (NASDAQ:ACST)

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

ACST Stock Price History

ACST Stock News Headlines

8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)
THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here:
Acasti Pharma Inc Class A
8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)
THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here:
Acasti announces $7.5M private placement equity funding
Acasti Pharma: Reverse Stock Split To Become Effective July 10
Acasti Pharma Announces 1-for-6 Reverse Stock Split
Recap: Acasti Pharma Q4 Earnings
Acasti Pharma's Earnings Outlook
See More Headlines
Receive ACST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/12/2024
Today
3/18/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
6/28/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ACST
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+76.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-42,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$200,000.00
Book Value
$9.14 per share

Miscellaneous

Free Float
8,129,000
Market Cap
$31.96 million
Optionable
Not Optionable
Beta
1.48
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Prashant Kohli (Age 52)
    CEO & Director
    Comp: $358.41k
  • Mr. Robert J. DelAversano CPA (Age 52)
    Principal Financial & Accounting Officer
  • Dr. R. Loch MacDonald M.D. (Age 62)
    Ph.D., Member of Scientific Advisory Board & Chief Medical Officer
  • Mr. Amresh Kumar Ph.D. (Age 44)
    VP of Program Management
  • Ms. Carrie D'Andrea (Age 52)
    VP of Clinical Operations

ACST Stock Analysis - Frequently Asked Questions

Should I buy or sell Acasti Pharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACST shares.
View ACST analyst ratings
or view top-rated stocks.

What is Acasti Pharma's stock price target for 2024?

1 equities research analysts have issued 12-month price objectives for Acasti Pharma's stock. Their ACST share price targets range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 76.5% from the stock's current price.
View analysts price targets for ACST
or view top-rated stocks among Wall Street analysts.

How have ACST shares performed in 2024?

Acasti Pharma's stock was trading at $2.89 at the beginning of the year. Since then, ACST stock has increased by 17.6% and is now trading at $3.40.
View the best growth stocks for 2024 here
.

Are investors shorting Acasti Pharma?

Acasti Pharma saw a increase in short interest in February. As of February 29th, there was short interest totaling 23,200 shares, an increase of 105.3% from the February 14th total of 11,300 shares. Based on an average trading volume of 28,600 shares, the short-interest ratio is currently 0.8 days. Approximately 0.3% of the company's stock are sold short.
View Acasti Pharma's Short Interest
.

When is Acasti Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, June 28th 2024.
View our ACST earnings forecast
.

How were Acasti Pharma's earnings last quarter?

Acasti Pharma Inc. (NASDAQ:ACST) posted its quarterly earnings results on Monday, February, 12th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.02.

When did Acasti Pharma's stock split?

Acasti Pharma shares reverse split on Monday, July 10th 2023. The 1-6 reverse split was announced on Monday, July 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of Acasti Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), SCYNEXIS (SCYX), Outlook Therapeutics (OTLK), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Heat Biologics (HTBX), KushCo (KSHB), Miragen Therapeutics (MGEN) and Aeterna Zentaris (AEZS).

Who are Acasti Pharma's major shareholders?

Acasti Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include ADAR1 Capital Management LLC (0.37%) and Royal Bank of Canada (0.34%). Insiders that own company stock include Donald Olds and Vimal Kavuru.
View institutional ownership trends
.

How do I buy shares of Acasti Pharma?

Shares of ACST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACST) was last updated on 3/18/2024 by MarketBeat.com Staff

From Our Partners